FDA
-
-
-
-
-
-
-
Carlyle, SK Capital Partners and bluebird bio (BLUE) Amend Merger Agreement
-
-
-
-
-
-
-
bluebird bio (BLUE) Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
-
-
-
-
-
-
-
bluebird bio Announces 1-for-20 Reverse Stock Split
-
-
-
-
-
-
-
bluebird bio (BLUE) Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025
-
-
-
-
-
-
-
bluebird bio Announces Second Quarter 2024 Results Call Date
-
-
-
-
-
-
-
BLUE DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important May 28 Deadline in Securities Class Action – BLUE
-
-
-
-
-
-
-
bluebird bio (BLUE) Completes First Cell Collection for LYFGENIA Gene Therapy
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

